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Bone metastasis of breast cancer induces severe osteolysis with increased bone resorption. Osteoclast differentiation regulated by
the receptor activator of NF-kB ligand (RANKL) in osteoblasts and matrix degradation induced by matrix metalloproteinases (MMPs)
are thought to be involved in the process of bone resorption. When nude mice were inoculated with human breast cancer cells,
MDA-MB-231(MDA-231), numerous osteoclasts resorbed bone and the degradation of the bone matrix markedly progressed in the
femur and tibia with metastasis of the MDA-231 tumour. The expression of RANKL, MMP-13 and membrane-type 1-MMP mRNA
was markedly elevated in bone with metastasis. When MDA-231 cells were cocultured with mouse calvaria, MDA-231 markedly
induced bone resorption measured by calcium release from the calvaria, and the expression of RANKL, MMP-2 and MMP-13 was
elevated in the calvaria after the coculture. The separation of MDA-231 from the calvaria using filter insert showed decreased bone
resorption, suggesting that cell-to-cell interaction is essential for cancer-induced bone resorption. Adding MDA-231 cells to bone
marrow cultures markedly induced osteoclast formation, and the expression of RANKL in osteoblasts was enhanced by contact with
the cell surface of MDA-231 cells. These results indicate that RANKL-induced osteoclast formation and MMP-dependent matrix
degradation are associated with osteolysis because of bone metastasis of breast cancer.
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Bone is the most common site of metastasis in breast cancer.
Tumour cells released from the primary focus infiltrate into the
blood vessels and reach bone to form skeletal metastasis. Bone
metastasis is accompanied by severe bone destruction, but the
molecular mechanisms of the tumour-induced bone resorption are
not fully understood. Previous studies have shown that bispho-
sphonate, an inhibitor of osteoclastic bone resorption, is a
beneficial agent for the treatment of bone metastasis in patients
with breast cancer (Hortobagyi et al, 1996). In an experimental
metastasis model using human breast cancer cells, bisphospho-
nates such as ibandronate suppress bone metastasis by the
promotion of apoptosis of osteoclasts (Hiraga et al, 2001). Using
the same model, a neutralising antibody to parathyroid hormone-
related protein (PTHrP) suppresses bone metastasis (Guise et al,
1996). PTHrP is a secreted peptide produced by tumours and
stimulates osteoclastic bone resorption (Powell et al, 1991).
Although PTHrP is one of the candidates for regulators in
tumour-induced osteolysis, other factors should also be involved
in the mechanism of bone resorption at the site of metastasis.
Recently, the mechanisms of bone resorption have been actively
examined, and the discovery of the receptor activator of NF-kB
ligand (RANKL) has allowed elucidation of the mechanism of
osteoclast differentiation in bone (Anderson et al, 1997; Wong et al,
1997; Lacey et al, 1998; Yasuda et al, 1998). Osteoblasts and bone
marrow stromal cells express RANKL as a membrane-associated
factor in response to bone-resorbing factors such as parathyroid
hormone (PTH), interleukin-1 (IL-1) and prostaglandin E2
(PGE2). Osteoclast precursors possess RANK, a receptor for
RANKL, and RANK–RANKL recognition induces the differentia-
tion of the precursors into osteoclasts. In osteolysis associated with
cancer metastasis, osteoclasts have to play an important role in the
process of bone resorption. Recent studies have shown that OPG
inhibits cancer-induced osteoclastogenesis and prevents tumour
growth in bone (Morony et al, 2001; Zhang et al, 2001), suggesting
that tumour cells use the RANKL:RANK axis to induce osteolysis.
Matrix metalloproteinase (MMP) is a family of proteolytic
enzymes involved in the degradation of the extracellular matrix of
various tissues including bone. More than 20 different mammalian
MMPs have been identified, and divided into four subgroups;
collagenase (MMP-1, MMP-8, MMP-13 and MMP-18), gelatinase
(MMP-2 and MMP-9), stromelysin (MMP-3 and MMP-10) and
membrane-type metalloproteinase (MMPs-14–17) (Mauviel, 1993;
Nagase and Woessner, 1999; Vu and Werb, 2000). It is known that
osteoblasts produce various MMPs such as MMP-1, MMP-2, MMP-
13 (collagenase 3) and MMP-14 (MT1-MMP), and that osteoclasts
selectively produce MMP-9 (MacDougall and Matrisian, 1995;
Kusano et al, 1998; Westermarck and Kahari, 1999). We have
reported that the induction of MMPs (such as MMP-2, -3 and -13)
in osteoblasts is essential for bone resorption (Kusano et al, 1998).
On the other hand, the roles of MMPs in infiltration and metastasis
of tumour cells have been widely investigated (MacDougall and
Matrisian, 1995; Nakahara et al, 1997; Westermarck and Kahari,
1999). MT1-MMP expressed in tumour cells activates proMMP-2
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sproduced by stromal cells in the primary focus and at the
metastatic site (Sato et al, 1994). Therefore, it is possible that
MMPs are involved in the process of bone metastasis. However, the
expression of MMPs in bone tissue with tumour metastasis and the
roles of these enzymes produced by host cells in tumour-induced
osteolysis have not been investigated as yet.
In this study, to clarify the role of RANKL-induced osteoclast
formation and MMP-dependent matrix degradation in osteolysis
because of bone metastasis, we examined the expression of RANKL
and MMPs in bone with metastasis using the intracardiac injection
of breast cancer cells. Expression of RANKL, MMP-2, MMP-13 and
MT1-MMP was markedly elevated in bone with metastasis of
breast cancer MDA-MB-231 cells in vivo. We established a new in
vitro system for cancer-induced bone resorption using tumour
cells cocultured with mouse calvaria, and found that cell-to-cell
interaction between tumour cells and osteoblasts induced the
expression of RANKL in osteoblasts, resulting in osteoclast
formation. We suggest that RANKL-induced osteoclast formation
and MMP-dependent matrix degradation are essential for osteo-
lysis because of bone metastasis.
MATERIALS AND METHODS
Animals, cells and reagents
Female BALB/c nu/nu (nude) mice (5 weeks old), and ddy mice,
day 2, day 5 and 6 weeks of age were obtained from Japan SLC Inc.
(Shizuoka, Japan). A human breast cancer cell line, MDA-MB-231
(MDA-231), was obtained from American Type Culture Collection
(Rockville, MD, USA). MDA-231 cells were cultured in a-modified
MEM (aMEM), supplemented with 10% fetal calf serum (FCS) at
371C under 5% CO2 in air. Recombinant human IL-1a (IL-1) and
recombinant mouse OPG were purchased from Genzyme/
TECHNE. BB94, a general inhibitor of MMPs, was kindly provided
by British Biotech Pharm., Ltd (Oxford, UK).
Intracardiac injections of MDA-231 in nude mice
MDA-231 cells (1 10
5) were suspended in 0.1ml of PBS and
injected into the left heart ventricle of 5-week-old female nude
mice with a 27-gauge needle under anaesthesia with pentobarbital.
Animals were kept in our specific pathogen-free animal facilities
for 6 weeks. All procedures were performed in accordance with
institutional guideline for animal research at the Tokyo University
of Pharmacy and Life Science.
Histological and radiographic analyses of the femur
and tibia
Radiographs of the femurs and tibiae were taken by soft X-ray
(model CMB-2; SOFTEX, Tokyo, Japan). The femurs and tibiae
were fixed with 70% ethanol and embedded in glycol methacrylate,
and undecalcified 3-mm sections were prepared and stained for
tartrate-resistant acid phosphatase (TRAP) or haematoxylin–eosin
(HE), as reported previously (Miyaura et al, 1997).
Northern blot analysis
Total RNA was extracted from the femur, tibia, cultured calvaria
and cultured mouse osteoblastic cells, using the acid guanidium–
phenol–chloroform method (Chen et al, 1997). For Northern
blotting, 20mg of total RNA was resolved using electrophoresis on
a 1% agarose–formaldehyde gel and transferred onto a nylon
membrane (Hybond-N, Amersham Pharmacia Biotech, Tokyo,
Japan), which was then hybridised with a
32P-labelled cDNA probe,
as reported previously (Chen et al, 1997). A 946-bp fragment of
mouse RANKL cDNA and a 485-bp fragment of mouse MMP-13
were prepared using RT–PCR cloning and used as the probes
(Kusano et al, 1998; Yasuda et al, 1998). Mouse MT1-MMP cDNA
was kindly provided by Dr M Seiki, and a 656-bp fragment was
used as the probe (Sato et al, 1994). The signals were
densitometrically quantified using an NIH-image analyzer.
RT–PCR analysis
cDNA was synthesised from 5mg of total RNA by reverse
transcriptase (Superscript II Preamplification System, Life Tech-
nologies, Grand Island, NY, USA) and amplified using PCR. The
primers used in PCR for the mouse RANKL gene were 50-GAC TCG
ACT CTG GAG AGT-30 (sense primer) and 50-GAG AAC TTG GGA
TTT TGA TGC-30 (antisense primer). The reaction conditions for
PCR were 32 cycles, denaturation at 941C for 45s, annealing at
581C for 45s and extension at 721C for 2min. The primers used in
PCR for the mouse cathepsin K gene were 50-CTT GTG GAC TGT
GTG ACT-30 (sense primer) and 50-AAC ACT GCA TGG TTC ACA-
30 (antisense primer). The reaction conditions for PCR were 25
cycles, denaturation at 941C for 45s, annealing at 551C for 45s and
extension at 721C for 2min. The primers used in PCR for the
mouse TRAP gene were 50-TGA CAA GAG GTT CCA GGA-30
(sense primer) and 50-AGC CAG GAC AGC TGA GTG-30 (antisense
primer). The reaction conditions for PCR were 25 cycles,
denaturation at 941C for 45s, annealing at 551C for 45s and
extension at 721C for 2min. The primers used in PCR for the
mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
were 50-TGA AGG TCG GTG TGA ACG GAT TTG GC-30 (sense
primer) and 50-CAT GTA GGC CAT GAG GTC CAC CAC-30
(antisense primer). The reaction conditions for PCR were 30
cycles, denaturation at 941C for 45s, annealing at 601C for 45s and
extension at 721C for 2min. The PCR product was run on a 1.5%
agarose gel and stained with ethidium bromide.
Coculture of MDA-231 cells and mouse calvaria
Ddy mice (5 days old) were killed and their calvariae were
aseptically harvested and dissected free of suture tissues. The
calvariae were divided into halves and cultured for 24h in 0.5ml
aMEM containing 1mgml
 1 BSA. After preculture for 24h, each
half calvaria was cocultured with MDA-231 cells (1 10
5)
embedded in 21ml of type I collagen gel (0.8mgml
 1) for the
positioning of coculture in 24-well plates. After 5 days of the
coculture, the calvaria with MDA-231 cells was fixed with 10%
formalin and used for histological analysis of TRAP and HE
staining. To determine the bone-resorbing activity in the
coculture, the concentration of calcium in the conditioned medium
was measured on day 5 with a calcium kit (calcium C-test Wako;
Wako Pure Chemical. Osaka, Japan). The conditioned medium was
also used for Western blot analysis and gelatin zymography for the
detection of MMP-2, MMP-9 and MMP-13. After the coculture,
MDA-231 cells in collagen gel were removed from the calvaria, and
the remaining calvariae were used for the extraction of total RNA
for Northern blot analysis. In some experiments, the calvaria was
separated from MDA-231 cells embedded in collagen gel using a
cell culture insert with an 8.0mm pore (FALCON, Becton
Dickinson, Franklin Lakes, NJ, USA).
Gelatin zymography
Gelatinase activity in the conditioned medium of the coculture of
the calvaria and MDA-231 cells embedded in collagen gel was
analysed by gelatin zymography (Kusano et al, 1998). Aliquots
(10ml) were mixed with 5ml of nonreducing SDS–PAGE sample
buffer, then subjected to SDS–PAGE using 10% polyacrylamide
gels containing 0.6mgml
 1 of gelatin. After electrophoresis, the
gels were incubated for 1h in washing buffer consisting of 50mM
Tris-HCl containing 5mM CaCl2,1 mM ZnCl2 and 2.5% Triton X-
100 to remove SDS, and then in the same buffer without Triton X-
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s100 at 371C for 1h. The gels were stained with 0.1% (wv
 1)
Coomassie Brilliant Blue in 50% (vv
 1) methanol, 10% (vv
 1)
acetic acid, and destained in a solution of 30% (vv
 1) methanol
and 1% (vv
 1) formic acid. Enzyme activity was detected as a clear
zone in a darkly stained background.
Western blot analysis
An aliquot of the conditioned medium of the coculture of calvaria
and MDA-231 cells embedded in collagen gel was subjected to
SDS–PAGE using 10% polyacrylamide gels and the separated
proteins were transferred to a polyvinylidene difluoride membrane
(PVDF, Millipore, Tokyo, Japan). The membrane was first
incubated for 18h at 41C with 5% skim milk in phosphate-
buffered saline containing 0.1% Tween-20 to block nonspecific
binding, and then incubated for 2h with polyclonal rabbit anti-
mouse MMP-13 antibody, kindly donated by Dr G Murphy. After
incubation with horseradish peroxidase-conjugated donkey anti-
rabbit IgG for 1h, immunoreactive bands were detected with an
ECL system (Amersham Pharmacia Biotech, Tokyo, Japan).
Cultures of primary mouse osteoblastic cells and
MDA-231 cells
Primary osteoblastic cells were isolated from 2-day-old mouse
calvariae after five routine sequential digestions with 0.1%
collagenase (Wako, Tokyo, Japan) and 0.2% dispase (Godo Shusei,
Tokyo, Japan), as described previously (Chen et al, 1997).
Osteoblastic cells collected from fractions 3 to 5 were combined
and cultured in aMEM supplemented with 10% FCS at 371C under
5% CO2 in air. In some experiments, the MDA-231 cells were fixed
with 3% paraformaldehyde and washed three times with culture
medium. On the layer of fixed-MDA-231 cells, osteoblasts and/or
bone marrow cells were cultured.
Osteoclast formation in coculture of mouse bone marrow
cells and osteoblasts
Bone marrow cells (2 10
6 cells) were isolated from 6-week-old
ddy mice, and cocultured with the primary osteoblasts (1 10
4
cells) in 0.5ml of aMEM containing 10% FCS in 24-well plates.
Primary osteoblastic cells were collected from newborn mouse
calvariae as described above. To examine the effects of MDA-231
cells on osteoclast formation, MDA-231 cells (1 10
4 cells) were
added to the coculture system. The cultures were fed every 3 days
by replacing 0.3ml of the old medium with fresh medium.
Reagents such as OPG were added at the beginning of the culture
and each time the medium was changed. After being cultured for 8
days, the cells adhering to the well surface were stained for TRAP.
The TRAP-positive multinucleated cells containing three or more
nuclei per cell were counted as osteoclasts.
Statistical analysis
The data are expressed as the means7s.e.m. The significance of
differences was analysed using the Student’s t-test.
RESULTS
Osteolysis due to bone metastasis of breast cancer cells
We first performed histological analyses in bone with metastasis of
breast cancer cells, MDA-231 cells, using a typical in vivo model.
Radiographic examination demonstrated the development of
metastatic osteolytic lesions in the femur and tibiae 6 weeks after
the injection of MDA-231 cells in nude mice (Figure 1). Tibiae were
collected from these mice, and used for histological examination of
the sections stained for HE and TRAP, a specific enzyme of
osteoclasts. Control tibia showed normal bone marrow cells and a
smooth cortical bone surface. The sections of tibia with osteolysis
indicated that metastatic tumour cells filled the bone marrow
cavity and that a number of TRAP-positive osteoclasts aligned on
the surface of the cortical bone and resorbed bone to form
resorption pits (Figure 1). The TRAP-staining of MDA-231 cells
was negative in the section of the metastatic region (Figure 1).
Expression of RANKL and MMPs in bone with metastasis
Using the model of bone metastasis of MDA-231 cells, we
examined the expression of RANKL and MMPs in bone with
metastasis. Figure 2A shows the radiographic data of mice used in
this experiment. Mouse A is control without injection of MDA-231
cells. Mouse B has severe osteolysis in the distal femur and slight
osteolysis in the proximal tibia. Mouse C shows severe osteolysis in
both the femur and tibia. From these mice, we collected the tibia
and femur to extract total RNA and used for Northern blot and
RT–PCR analyses to detect the mRNA expression of RANKL and
MMPs. It is well known that cathepsin K and TRAP are specifically
Control Metastasis
X-ray
D C
F E
HE
TRAP CB CB BM
CB
BM
OC
OC
Tumor
CB
OC
OC
Tumor
Femur
Tibia
A B
Figure 1 Representative radiographs and histological sections of
osteolytic lesions in the hindlimbs of nude mice injected with MDA-231
cells. (A, B) Soft X-ray analyses of the hindlimbs of control mouse injected
with PBS (A) and mouse injected with MDA-231 cells (B). Arrowhead
indicates the osteolytic lesion because of metastasis in the tibia. (C, D)H E
staining of histological sections of tibia collected from the mice shown in
panels A and B, respectively. In the control section (C), bone marrow cells
(BM) were normal and the cortical bone (CB) surface was smooth. In the
metastasised section (D), tumour filled the bone marrow cavity and
replaced the cellular elements. Arrows indicate osteoclasts (OC) on the
cortical surface. (E, F) TRAP staining of the serial sections of panels C and
D, respectively. In the metastasized section (F), TRAP-positive osteoclasts
were aligned on the cortical surface.
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sexpressed in osteoclasts (Minkin, 1982; Saftig et al, 1998). The
expression of cathepsin K and TRAP was markedly elevated in the
femur of mouse B and in the femur and tibia of mouse C,
indicating that osteoclastic bone resorption was in progress in
these bones (Figure 2B). The expression of RANKL mRNA was
hardly detected in bone without metastasis, but bone with severe
metastasis exhibited a marked expression of RANKL mRNA.
MMP-13 is a critical enzyme for the degradation of type I collagen,
and is known to be produced by osteoblasts treated with bone-
resorbing factors (Kusano et al, 1998). The expression of MMP-13
mRNA was slightly detected in control bone in mouse A, and
greatly elevated in bone with severe osteolysis in mice B and C
(Figure 2C). MT1-MMP (MMP-14) is known to activate pro-MMP-
2 and pro-MMP-13, and is essential for bone remodelling (Sato
et al, 1994; Knauper et al, 1996; Holmbeck et al, 1999; Zhou et al,
2000). The expression of MT1-MMP mRNA was hardly detected in
bone without metastasis, but bone with severe osteolysis showed a
marked expression of MT1-MMP (Figure 2C). In RT–PCR using
human-specific primers for RANKL and MMP-13, we detected no
expression of RANKL and MMP-13 mRNAs not only in MDA cells
cultured in vitro but also in bone with severe metastasis (data not
shown). This suggests that the expression of RANKL and MMPs
detected in bone with severe osteolysis was mostly derived from
bone in nude mice.
Coculture of MDA-231 cells in collagen gel and mouse
calvaria
To examine the mechanism of tumour-induced bone resorption,
we developed a new in vitro system using MDA-231 cells and
calvaria collected from 5-day-old mice. MDA-231 cells were
embedded in type I collagen gel to retain the position and
cocultured for 5 days with mouse calvaria. Histological analysis
showed that some MDA-231 cells in the collagen gel were in
contact with the surface of the calvaria and that TRAP-positive
osteoclasts formed resorption pits in the side of the calvaria
attached to MDA-231 cells (Figure 3C, D). In calvaria treated with
2ngml
 1 of IL-1, on the other hand, osteoclasts resorbed calcified
bone on the inside of the calvaria (Figure 3E, F).
Bone-resorbing activity and expression of RANKL and
MMPs in coculture of MDA cells and mouse calvaria
Using the coculture system of MDA-231 cells and mouse calvaria,
we examined the bone-resorbing activity by measuring medium
calcium. When calvarial tissues were cocultured for 5 days with
MDA-231 cells, the bone-resorbing activity was markedly elevated
and the level was similar to that induced by 2ngml
 1 of IL-1
(Figure 4B). After the coculture, MDA-231 cells were removed
from the calvarial tissues, and the expression of RANKL in the
calvaria was examined by Northern blot analysis. In consistence
with the data of bone-resorbing activity, the expression of RANKL
mRNA was elevated in the calvaria cocultured with MDA-231 cells
(Figure 4C). In this study, we also examined the expression of
MMP-2, MMP-9 and MMP-13 by gelatin zymography and Western
blot analysis. Gelatin zymography using the conditioned medium
of the coculture revealed an enhanced production of pro-MMP-2,
active-MMP-2 and pro-MMP-9. The production of MMP-13 was
also elevated in the coculture with MDA-231 cells (Figure 4D). The
level of MMP-2 and MMP-13 in the coculture was similar to that in
the calvaria treated with 2ngml
 1 of IL-1. In RT–PCR using
human-specific primers for RANKL and MMP-13, the expression
of their mRNAs could not be detected in both control MDA-231
cells and MDA-231 cells cocultured with calvaria (data not shown).
Mechanisms of tumour-induced bone resorption
To examine the role of RANKL and MMPs in bone resorption
induced by MDA-231 cells, we added 100ngml
 1 of OPG, a decoy
receptor for RANKL, and 10mM BB94, a general inhibitor of MMPs,
to the coculture of mouse calvaria and MDA-231 cells. The bone-
resorbing activity induced by MDA-231 cells was significantly
suppressed by adding OPG and BB94 on day 5 (Figure 5B).
Therefore, both RANKL and MMPs are involved in the mechanism
of bone resorption induced by MDA-231 cells. Adding OPG and
BB94 had little influence on the expression of RANKL mRNA in
the coculture (Figure 5C). Adding OPG and BB94 showed no effect
on growth of MDA-231 cells (data not shown).
Previous studies have shown the roles of soluble factors, such as
PTHrP, produced by tumour cells in bone metastasis (Powell et al,
1991; Pederson et al, 1999). On the other hand, cell-to-cell
interaction between tumour cells and stromal cells is thought to be
essential for the production of cytokines and MMPs. To determine
this point, the calvaria was separated from MDA-231 cells on day 5
in the coculture, as shown in Figure 5A. The bone-resorbing
X-ray
Tibia
Femur
A
B
C
Osteolysis
RANKL
TRAP
GAPDH
Cathepsin K
Mouse A Mouse B Mouse C
Tibia
−
Femur
−
Tibia
+
Femur
+++
Tibia
+++
Femur
+++
Mouse A Mouse B Mouse C MDA
Tibia Femur Tibia Femur Tibia Femur
Mouse A Mouse B Mouse C MDA
Tibia Femur Tibia Femur Tibia Femur
MMP-13
MT1-MMP
28S rRNA
Figure 2 Expression of RANKL, cathepsin K, TRAP, MMP-13 and MT1-
MMP mRNA in bone with metastasis of MDA-231 breast cancer. (A)
Nude mice were injected with or without MDA-231 cells and the
hindlimbs were subjected to soft X-ray analyses. Arrowheads indicate the
osteolytic lesions because of metastasis in the femur and tibia. Mouse A is
control mouse without injection of MDA-231 cells. Mouse B possesses
slight metastasis in the tibia and severe metastasis in the femur. Mouse C
possesses severe metastasis in both the femur and tibia. (B) Total RNA
was collected from the femur and tibia shown in panel A, and mRNA
expression of RANKL, cathepsin K and TRAP was analysed by RT–PCR.
(C) Expression of MMP-13 and MT1-MMP mRNAs was analysed by
Northern blotting using total RNA used in panel B. Note that marked
expression of RANKL, cathepsin K, TRAP, MMP-13 and MT1-MMP
mRNAs was detected only in bone with severe osteolysis because of bone
metastasis.
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sactivity induced by MDA-231 cells was significantly suppressed
when the calvaria was separated from MDA-231 cells (Figure 5B).
The level of expression of RANKL mRNA was reduced in a
separate coculture, but the level was still higher than that in
controls (Figure 5C). These results suggest that cell-to-cell and cell-
to-matrix interaction is essential for tumour-induced bone
resorption, and that a soluble factor(s) produced by tumours is
partially involved in the mechanism of bone resorption induced by
breast cancer cells.
Osteoclast formation induced by breast cancer
cells in vitro
In place of osteolysis because of bone metastasis, numerous
osteoclasts appear on the surface of bone in vivo, as shown in
HE TRAP
A B
C D
E F
OC
OC OC
OC
OC OC OC
OC
Cal Cal
Cal Cal
Cal Cal
Gel Gel
MDA MDA
Figure 3 Histological view of coculture of mouse calvaria and MDA-231
breast cancer cells embedded in collagen gel. Calvariae were collected from
5-day-old mice, and cocultured for 5 days with MDA-231 cells, embedded
in type I collagen gel to retain the position in culture plates. After the
culture, the calvariae were fixed, sectioned and stained for HE and TRAP.
(A, B) Section of the control calvaria. (C, D) Section of the coculture of
calvaria and MDA-231 cells embedded in the gel. Osteoclasts and
resorption pits were observed on the surface of the calvaria in contact with
the gel containing MDA-231 cells. (E, F) As the positive control, calvariae
were cultured for 5 days in the presence of 2ngml
 1 of IL-1. Osteocalsts
were observed inside the calvaria. Cal, calvaria; OC, osteoclasts; Gel, type I
collagen gel; MDA, MDA-MD-231.
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Figure 4 Bone-resorbing activity and expression of RANKL and MMPs in
coculture of mouse calvaria and MDA-231 cells. (A) Illustrations of the
experimental procedure of coculture of mouse calvaria and MDA-231 cells.
Mouse calvariae were cocultured for 5 days with MDA-231 cells. As a
positive control of bone resorption, calvariae were cultured for 5 days with
2ngml
 1 of IL-1. MDA-231 cells (1 10
5 cells) were cultured for 5 days as
MDA-231 control without calvaria. (B) Conditioned media were collected,
and the concentration of calcium in the medium was measured to monitor
the bone-resorbing activity. Data are expressed as means7s.e.m. of six
cultures. Significantly different from the control (*Po0.001). (C) Total
RNA was extracted from calvaria-excluded MDA-231 cells, and Northern
blotting was performed using
32P-labelled cDNA probes for RANKL as
described in Materials and Methods. (D) Conditioned media were
collected and gelatin zymography (upper panel) and Western blotting
(lower panel) were performed as described in Materials and Methods. In
the upper panel, gelatinase activities corresponding to pro-MMP-2, active-
MMP-2 and pro-MMP-9 are indicated by arrows. In the lower panel, MMP-
13 was detected using anti-mouse MMP-13 antibody. Note that the
marked expression of RANKL, MMP-2 and MMP-13 was detected in the
calvaria cocultured with MDA-231 cells, and that the levels were similar to
those indued by IL-1.
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sFigure 1. To test whether osteoclasts are formed by the presence of
tumour cells in vitro, we added MDA-231 cells to the coculture
of mouse bone marrow cells and osteoblasts. Usually, the addition
of bone-resorbing factors is essential for osteoclast formation in
the coculture system. However, as shown in Figure 6, adding MDA-
231 cells markedly induced osteoclast formation on day 8 without
exogenous bone-resorbing factor. The osteoclast formation
induced by MDA-231 cells was completely abolished by adding
100ngml
 1 of OPG (Figure 6). In addition, when MDA-231 cells
were separated from the bone marrow cells and osteoblasts using a
cell culture insert, osteoclasts were not formed on day 8 in the
coculture. Therefore, cell-to-cell interaction is essential for MDA-
231-induced osteoclast formation.
Adhesion to fixed MDA-231 cells induces the expression of
RANKL in osteoblasts and osteoclast formation
We next examined the effects of the adhesion of MDA-231 cells on
the expression of RANKL mRNA in osteoblasts. MDA-231 cells
were fixed with paraformaldehyde in the well, and mouse
osteoblasts were added. At 3h after adding the osteoblasts, the
expression of RANKL mRNAs was elevated in the osteoblasts
compared with the control osteoblasts without MDA-231 cells
(Figure 7B). These results indicate that cell-to-cell contact between
MDA-231 cells and osteoblasts induces the expression of RANKL
on the surface of osteoblasts. Indeed, adding fixed MDA-231 cells
could induce osteoclast formation on day 8 in a coculture of bone
marrow cells and osteoblasts without any exogenous bone-
resorbing factor (Figure 7A).
DISCUSSION
The present study demonstrated that the expression of RANKL
and MMPs including MMP-13 and MT1-MMP was markedly
elevated in bone with metastasis in vivo, and that the levels of
expression of RANKL and MMPs were correlated with the extent of
osteolysis (Figure 2). To examine the mechanism of bone
resorption induced by tumour cells, we established a new coculture
system of mouse calvaria and MDA-231 cells embedded in collagen
gel, and found that MDA-231 cells markedly induced the bone-
resorbing activity, the expression of RANKL in calvaria and the
production of MMPs including MMP-2, MMP-9 and MMP-13 by
calvaria (Figures 3 and 4).
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Figure 5 Roles of RANKL, MMPs and interaction between bone and
tumour cells in bone-resorbing activity in coculture of calvariae and MDA-
231 cells. (A) Illustrations of the experimental procedure of coculture and
separate coculture using 5-day-old mouse calvaria and MDA-231 cells
embedded in collagen gel. In separate cocultures, calvariae were separated
from MDA-231 cells using cell culture inserts, which permeate soluble
factors present in the culture media. (B) Bone-resorbing activity was
measured by the increase in medium calcium using conditioned media
collected on day 5 from coculture and separate coculture shown in panel
A. In the cocultures, a subgroup was added to osteoprotegerin (OPG:
100ngml
 1) or BB94 (10mM). Some calvariae were cultured with
2ngml
 1 of IL-1 as positive control of bone resorption. MDA-231 cells
(1 10
5 cells) were cultured on plate for 5 days as control without calvaria
(MDA only). Data are expressed as means7s.e.m. of six cultures.
Significantly different from the value of coculture with MDA-231
(*Po0.001). (C) Total RNA was extracted from the calvaria used in the
experiment shown in panel B, and Northern blotting was performed using
32P-labelled cDNA probe for RANKL. In the cocultures, MDA-231 cells in
the collagen gel were removed from the calvaria prior to the extraction of
total RNA from the calvaria.
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Figure 6 Osteoclast formation induced by MDA-231 cells in cocultures
of mouse bone marrow cells and osteoblasts. Mouse bone marrow cells
(2 10
6) and osteoblasts (1 10
4) were cocultured for 8 days with MDA-
231 cells (1 10
4) in the presence or absence of 100ngml
 1 of OPG. In a
separate coculture, MDA-231 cells were separated from bone marrow
cells and osteoblasts using a cell culture insert. (A) Representative field of
TRAP staining. (B) The number of TRAP-positive multinucleated cells
(MNCs) containing three or more nuclei was counted. Data are expressed
as the means7s.e.m. of three wells. Significantly different from the control
(*Po0.001).
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sRecent studies have shown that RANKL expressed on the surface
of osteoblasts is essential for osteoclast formation, and that
osteoclast precursors, expressing RANK, recognise RANKL for
their differentiation into mature osteoclasts (Anderson et al, 1997;
Wong et al, 1997; Lacey et al, 1998; Yasuda et al, 1998). Adding
MDA-231 cells to the coculture of mouse bone marrow cells and
osteoblasts induced osteoclast formation without the requirement
for any bone-resorbing factors (Figure 6). Using species-specific
primers for RT–PCR, we distinguished the mRNA expression of
human RANKL from that of mouse RANKL. MDA-231 cells
showed no expression of human RANKL, whether bone cells were
present or not (data not shown). Therefore, RANKL is expressed in
host bone cells rather than MDA-231 cells. Zhang et al (2001) have
reported that prostate cancer cells produce a soluble form of
RANKL and directly induce osteoclastogenesis from osteoclast
precursors. Although the tumour-induced osteoclastogenesis is
mostly RANKL-dependent, the mechanism may be reliant on the
tumour cells in each case.
OPG, an inhibitory molecule for osteoclastogenesis, binds to
RANKL as a decoy receptor and suppresses the interaction
between RANKL and RANK (Simonet et al, 1997; Tsuda et al,
1997; Kwon et al, 1998). Recent studies suggest that OPG may be a
new therapeutic agent for bone loss associated with metabolic
diseases such as osteoporosis and rheumatoid arthritis (Bucay et al,
1998; Kong et al, 1999; Kostenuik et al, 2001; Redlich et al, 2002).
In the present study, OPG suppressed both bone resorption
induced by MDA-231 cells in calvarial cultures and osteoclast
formation induced by MDA-231 cells in bone marrow cultures.
This is consistent with recent papers describing that tumour cells
such as B16 melanoma and neuroblastoma induce osteoclast
formation by a RANKL-dependent mechanism in vitro (Chikatsu
et al, 2000; Michigami et al, 2001).
Bone resorption is mediated by not only osteoclast differentia-
tion, but also matrix degradation. Cathepsin K and MMP-9 are
selectively produced by osteoclasts in bone, but MMP-2, MMP-13
and MT1-MMP are mainly expressed in osteoblasts (Meikle et al,
1992; Reponen et al, 1994; Kinoh et al, 1996; Kusano et al, 1998).
We have reported that bone-resorbing factors such as IL-1 and
PGE2 markedly induced the expression of MMPs including MMP-
2, MMP-3 and MMP-13, and that the induction of MMPs was
associated with an increase in bone-resorbing activity in mouse
calvarial cultures (Kusano et al, 1998; Miyaura et al, 2000). Other
reports have also shown that MMPs are involved in the process of
bone resorption (Hill et al, 1994). In the present study, we detected
a marked expression of MMP-13 and MT1-MMP in bone with
metastasis in vivo (Figure 2). In coculture of mouse calvaria and
MDA-231 cells, the production of MMP-2, MMP-9 and MMP-13
was markedly enhanced, and adding BB94, a general inhibitor of
MMPs, significantly suppressed the bone-resorbing activity
elicited by MDA-231 cells (Figures 4 and 5). Therefore, MMPs
produced by osteoblasts and osteoclasts may contribute to the
matrix degradation at the site of tumour-induced osteolysis.
MMPs are known to be involved in several processes of cancer
metastasis. Infiltration of tumour cells from the blood vessels and
invasion into metastatic organs are regulated by MMPs such as
MMP-2 and MT1-MMP produced by host cells as well as tumour
cells (MacDougall and Matrisian, 1995; Nakahara et al, 1997;
Westermarck and Kahari, 1999). Yoneda et al (1997) have reported
that osteolytic bone metastasis of breast cancer could be inhibited
by combined treatment with bisphosphonate, a specific inhibitor
of osteoclastic bone resorption, and tissue inhibitor of MMP
(TIMP)-2, a natural inhibitor of MMPs. Since previous studies
have shown that recombinant TIMP-1 and TIMP-2 inhibited bone
resorption in vitro (Hill et al, 1993), TIMP-2 may suppress bone
metastasis by inhibiting both tumour invasion and bone resorp-
tion.
Previous reports have shown that cancer cells produce various
humoral factors such as PTHrP and bone-resorbing cytokines
(Powell et al, 1991; Pederson et al, 1999). It is possible that a
soluble factor(s) produced by tumour cells is involved in the
mechanism of tumour-induced osteolysis. PTHrP was reported to
contribute to breast cancer-mediated osteolysis (Powell et al,
1991), and anti-PTHrP neutralising antibody was shown to be
effective in osteolysis (Guise et al, 1996). Mancino et al (2001) have
reported that MDA-231 cells stimulate osteoclast formation by
secreting macropahge colony-stimulating factor (M-CSF) and by
enhancing the expression of RANKL in stromal support cells. It is
well known that M-CSF produced by osteoblastic stromal cells is
essential for osteoclast formation. In the present study, the bone-
resorbing activity induced by MDA-231 cells was significantly
suppressed when the calvaria was separated from MDA-231 cells,
but the activity was still higher than that of controls in calvarial
cultures (Figure 5). Therefore, bone resorption induced by MDA-
231 cells may be due in part to humoral factors such as PTHrP and
M-CSF produced by MDA-231 cells. On the other hand, cell-to-cell
interaction seems to play an important role in osteoclast formation
induced by MDA-231 cells, because osteoclast formation was
completely suppressed when MDA-231 cells were separated from
bone marrow cells (Figure 6).
To examine the role of cell-to-cell interaction between tumour
cells and host cells in osteoclast formation, we fixed MDA-231 cells
before the contact with bone marrow cells. Fixed MDA-231 cells
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Figure 7 Cell-to-cell contact between osteoblasts and fixed-MDA-231
cells induces RANKL expression in osteoblasts, and osteoclast formation in
coculture of bone marrow cells and osteoblasts. (A) Subconfluent MDA-
231 cells were fixed with paraformaldehyde and washed with culture
medium. Mouse bone marrow cells and osteoblasts were cocultured for 8
days on the layer of fixed-MDA-231 cells. Red colour staining shows
representative field of TRAP staining. (B) Mouse osteoblasts were added
to a culture dish (control) or the layer of fixed-MDA-231 cells (fixed-
MDA), and cultured for 3h to extract total RNA. Northern blotting was
performed using
32P-labelled cDNA probe for RANKL. Signals in the upper
panel were quantified using an image analyser as shown in the lower panel.
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expression of RANKL in mouse osteoblasts (Figure 7), indicating
that molecule(s) expressed on the surface of MDA-231 cells may be
recognised by osteoblasts. Osteoblasts as well as tumour cells
express various integrins, and integrin signals are known to
regulate osteoclast formation (Matsuura et al, 1996; Akatsu et al,
1998; Pommerenke et al, 2002). The molecules involved in cell-to-
cell recognition between MDA-231 cells and osteoblasts and the
signal transduction for RANKL expression in osteoblasts are under
investigation in our laboratory.
In conclusion, our present study demonstrated that the
expression of RANKL and MMPs was markedly elevated in bone
with osteolytic metastasis in vivo, and that breast cancer cells
induced osteoclast formation by a mechanism involving cell-to-cell
interaction between cancer cells and osteoblasts. Both RANKL-
induced osteoclastogenesis and MMP-dependent matrix degrada-
tion may contribute to osteolysis because of bone metastasis.
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